Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and Grifols, S.A.

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ascendis Pharma A/S and Grifols, S.A. over the past decade.

Ascendis Pharma A/S: A Rapid Climb

From 2014 to 2023, Ascendis Pharma A/S witnessed a staggering increase in SG&A expenses, growing by over 4,100%. Starting at a modest $6.3 million in 2014, the expenses soared to $264 million by 2023. This growth reflects the company's aggressive expansion and investment in operational capabilities.

Grifols, S.A.: Steady and Strong

In contrast, Grifols, S.A. maintained a steady growth trajectory, with SG&A expenses increasing by approximately 90% over the same period. From $661 million in 2014 to $1.25 billion in 2023, Grifols' consistent rise underscores its stable market presence and strategic cost management.